Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia

Christina Poh, Mili Arora, Sudeep Ghuman, Joseph Tuscano

Research output: Contribution to journalArticle

Abstract

T-cell large granular lymphocyte (LGL) leukemia is a rare indolent neoplasm primarily treated with immunosuppression. Few therapies and no consensus exist for the optimal treatment of T-cell LGL leukemia refractory to immunosuppressive therapy. Here, we report a case of relapsed/refractory T-cell LGL treated with belinostat. A 57-year-old male presented with lymphocytosis and anemia and was found to have T-cell LGL, requiring frequent packed red blood cell transfusions. He was initially treated with methotrexate with no response after 7 months. He was then switched to cyclosporine and cyclophosphamide and experienced transfusion independence for 42 months before disease relapse. He was then started on belinostat with noted subsequent transfusion independence for greater than 15 months to date and decreased disease involvement on bone marrow biopsy. To our knowledge, this is the first reported case of belinostat use in relapsed/refractory T-cell LGL leukemia which resulted in a durable clinical and biologic response.

Original languageEnglish (US)
JournalActa Haematologica
DOIs
StateAccepted/In press - Jan 1 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia'. Together they form a unique fingerprint.

  • Cite this